酒石酸去氧肾上腺素 | 17162-39-9

• 分子结构分类: 有机化合物 - 有机氧化合物
• 中文名称: 酒石酸去氧肾上腺素
• 中文别名: L-重酒石酸去氧肾上腺素；重酒石酸去氧肾上腺素；重酒石酸-L-苯肾上腺素；3-[(1R)-1-羟基-2-(甲基氨基)乙基]苯酚2,3-二羟基琥珀酸盐(1:1)
• 英文名称: Phenylephrine bitartrate
• 英文别名: 2,3-dihydroxybutanedioic acid;3-[1-hydroxy-2-(methylamino)ethyl]phenol
• CAS: 17162-39-9；14787-58-7
• 化学式: C13H19NO8
• 分子量: 317.29
• InChiKey: NHKOTKKHHYKARN-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -1.48
• 重原子数：
  22
• 可旋转键数：
  6
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.38
• 拓扑面积：
  168
• 氢给体数：
  7
• 氢受体数：
  9

安全信息

• 海关编码：
  2922509090
• WGK Germany：
  3

文献信息

• Nasal and Ophthalmic Delivery of Aqueous Corticosteroid Solutions
  申请人：Pipkin James D.

  公开号：US20090312724A1

  公开（公告）日：2009-12-17

  The present invention is directed to methods of treating nasal and/or ophthalmic diseases, symptoms, or disorders that are therapeutically responsive to corticosteroid therapy by delivering aqueous solution formulations comprising a corticosteroid to nasal and ophthalmic tissues. The invention is also directed to methods, systems, devices, and compositions for delivering aqueous solution formulations comprising a corticosteroid and an antihistamine to nasal and ophthalmic tissues.

  本发明涉及通过给鼻腔和眼科组织提供含有皮质类固醇的水溶液制剂，治疗对皮质类固醇疗法有治疗反应的鼻部和/或眼科疾病、症状或障碍的方法。本发明还涉及用于给鼻腔和眼科组织提供含有皮质类固醇和抗组胺剂的水溶液制剂的方法、系统、装置和组合物。
• BENZONATATE MODIFIED RELEASE SOLID TABLETS AND CAPSULES
  申请人：TRIS Pharma Inc.

  公开号：US20160199341A1

  公开（公告）日：2016-07-14

  A 12-hour anti-tussive modified release solid tablet or capsule is described which comprises a benzonatate adsorbate in a matrix with a sufficient amount of one or more pharmaceutically acceptable modified release pH-independent, substances to provide a 12-hour modified release profile to the benzonatate, wherein there is substantially no benzonatate release from the tablet or capsule in the buccal cavity and no more than about 25% release of the benzonatate within 1 hour as determined in an in vitro dissolution assay.

  本发明描述了一种12小时的抗咳嗽缓释固体片剂或胶囊，其包含苯佐卡因吸附剂在基质中，并添加了足够量的一种或多种药学上可接受的缓释pH独立物质，以提供苯佐卡因的12小时缓释特性。其中，在口腔中基本上没有苯佐卡因从片剂或胶囊中释放，在体外溶解试验中，1小时内苯佐卡因的释放不超过25%。
• Stable acetylsalicylic acid and diphenhydramine citrate effervescent composition
  申请人：MILES LABORATORIES, INC.

  公开号：EP0194547A2

  公开（公告）日：1986-09-17

  A substantially stable composition containing an effervescent couple, acetylsalicylic acid and diphenhydramine citrate is disclosed. Other known active agents, as well as optional ingredients such as flavorings, may also be included in the composition. The composition effervesces when placed m water The effervescent couple preferably is sodium bicarbonate and citric acid.

  本发明公开了一种基本稳定的组合物，其中含有泡腾剂、乙酰水杨酸和柠檬酸苯海拉明。组合物中还可加入其他已知的活性剂以及香料等可选成分。泡腾剂最好是碳酸氢钠和柠檬酸。
• Skin penetration system for salts of amine-functional drugs
  申请人：THE PROCTER & GAMBLE COMPANY

  公开号：EP0351897A2

  公开（公告）日：1990-01-24

  The invention involves pharmaceutical compositions for topical application comprising: (a) a pharmaceutically-acceptable salt of addition of an amine-functional drug (other than opioid analgesic drugs); (b) a C₇ to C₂₂ straight-chain or branched-chain, saturated or unsaturated, fatty acid having a melting point of less than about 50°C; and (c) a C₃-C₄ alkane diol.

  本发明涉及用于局部应用的药物组合物，包括 (a) 一种胺功能药物（阿片类镇痛药除外）的药学上可接受的加成盐； (b) C₇ 至 C₂₂ 直链或支链、饱和或不饱和脂肪酸，熔点低于约 50°C；以及 (c) C₃-C₄ 烷二醇。
• Effervescent cold or sinus allergy medicine composition having reduced sodium content
  申请人：BAYER AG

  公开号：EP0418564A1

  公开（公告）日：1991-03-27

  An effervescent cold or sinus allergy medicine composition having reduced sodium content is produced from a mixture of an analgesic, such as acetylsali­cylic acid, acetaminophen, ketoprofen, or a mixture thereof, citric acid, sodium bicarbonate, calcium carbonate, potassium bicarbonate, antihistamine, decongestant, and minor amounts of flavors and sweeteners.

  一种钠含量较低的泡腾感冒或鼻窦过敏药物组合物是由镇痛剂（如乙酰水杨酸、对乙酰氨基酚、酮洛芬或它们的混合物）、柠檬酸、碳酸氢钠、碳酸钙、碳酸氢钾、抗组胺剂、减充血剂以及少量香精和甜味剂的混合物制成的。

表征谱图